These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7841575)

  • 1. Intralipid in prophylaxis of amphotericin B nephrotoxicity.
    Vita E; Schroeder DJ
    Ann Pharmacother; 1994 Oct; 28(10):1182-3. PubMed ID: 7841575
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of nephrotoxicity with the administration of amphotericin B in a lipid emulsion.
    Smith TM; Strozyk WR
    Ann Pharmacother; 1994 Nov; 28(11):1307-8. PubMed ID: 7849357
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Herbrecht R; Letscher V
    J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
    Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
    Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
    Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
    J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation.
    Branch RA
    Arch Intern Med; 1988 Nov; 148(11):2389-94. PubMed ID: 3056312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline.
    Branch RA; Jackson EK; Jacqz E; Stein R; Ray WA; Ohnhaus EE; Meusers P; Heidemann H
    Klin Wochenschr; 1987 Jun; 65(11):500-6. PubMed ID: 3475498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is liposomal amphotericin B really safety in neonates?
    Karadag-Oncel E; Ozsurekci Y; Yurdakok M; Kara A
    Early Hum Dev; 2013 Jan; 89(1):35-6. PubMed ID: 22877627
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to "is liposomal amphotericin B really safety in neonates?".
    Manzoni P; Rizzollo S; Farina D
    Early Hum Dev; 2013 Jan; 89(1):37. PubMed ID: 22831635
    [No Abstract]   [Full Text] [Related]  

  • 11. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function.
    Burgess JL; Birchall R
    Am J Med; 1972 Jul; 53(1):77-84. PubMed ID: 4667504
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function.
    Burges JL; Birchall R
    Am J Med; 1972 Jul; 53(1):77-84. PubMed ID: 5037291
    [No Abstract]   [Full Text] [Related]  

  • 13. Nephrotoxicity in the setting of invasive fungal diseases.
    Ullmann AJ
    Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Sievers TM; Kubak BM; Wong-Beringer A
    J Antimicrob Chemother; 1996 Sep; 38(3):333-47. PubMed ID: 8889711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin B: a second look.
    Medoff G; Kobayashi GS
    Compr Ther; 1977 Jul; 3(7):20-4. PubMed ID: 880788
    [No Abstract]   [Full Text] [Related]  

  • 17. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J; Markham L; Matulionyte R; Rives V; Lew D
    Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care?
    Anderson CM
    West J Med; 1995 Apr; 162(4):313-7. PubMed ID: 7747495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical correlations during amphotericin B therapy.
    Goodpasture HC; Voth DW; Romig DA; Cheng D; Wenglin BD; Liu C
    J Kans Med Soc; 1972 Nov; 78(11):486-90. PubMed ID: 5078570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.